NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Hester Biosciences Re-appoints Rajiv Gandhi as CEO & MD for 3 Years with 99.54% Approval
Hester Biosciences has announced the successful re-appointment of Mr. Rajiv Gandhi as CEO and Managing Director for a three-year term effective from April 1, 2026. The special resolution was passed via a postal ballot process with an overwhelming 99.54% of valid votes cast in favor. While the promoter group showed 100% support, a significant majority of the small institutional voting block (99.24%) voted against the resolution. This move ensures leadership continuity for the company through March 2029.
முக்கிய அம்சங்கள்
Special resolution for re-appointment of Rajiv Gandhi as CEO & MD passed with 99.54% majority.The new term is effective for three years from April 1, 2026, to March 31, 2029.Total valid votes cast represented 4,075,085 shares, with 4,056,419 votes in favor.Promoter group cast 3,451,082 votes, showing 100% internal support for the leadership.Public institutional holders showed 99.24% dissent, though this represented only 18,570 shares.
👀 கவனிக்க வேண்டியவை
Investors should take confidence in the leadership continuity which supports long-term strategic stability. No immediate action is required as the current management remains at the helm.
Tasty Bite Appoints Industry Veteran Tushar Srivastava as Senior Director of Food Service
Tasty Bite Eatables Limited has appointed Mr. Tushar Srivastava as the Senior Director for its Tasty Bite Food Service (TFS) division, effective March 09, 2026. Mr. Srivastava brings over 28 years of extensive experience from major FMCG and food companies including PepsiCo, Walmart, and Jubilant FoodWorks. His expertise spans across General Trade, HoReCa, and E-commerce, which is critical for scaling the company's institutional and food service business. This strategic hire is expected to strengthen the company's go-to-market strategies and drive profitable growth in the B2B segment.
முக்கிய அம்சங்கள்
Appointment of Tushar Srivastava as Senior Director - TFS effective March 09, 2026Candidate brings over 28 years of experience from top-tier firms like P&G, Kellogg's, and PepsiCoExpertise includes leadership roles at Jubilant FoodWorks and Walmart, focusing on HoReCa and retail channelsEducational background includes a PG in Marketing and an Executive General Management Programme from IIM Bangalore
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive step towards strengthening the institutional business segment. Monitor the company's performance in the Food Service (TFS) division over the coming quarters to gauge the impact of this leadership addition.
SBI Cards Declares Interim Dividend of Rs 2.50 Per Share for FY 2025-26
The Board of Directors of SBI Cards and Payment Services Limited has declared an interim dividend of Rs. 2.50 per equity share for the financial year 2025-26. This payout represents 25% of the face value of Rs. 10 per share. The company has established March 11, 2026, as the record date to identify eligible shareholders. Following new SEBI regulations, the dividend will be distributed solely through electronic modes, with no physical warrants or cheques being issued.
முக்கிய அம்சங்கள்
Interim dividend declared at Rs. 2.50 per equity share (25% of face value).Record date for dividend entitlement is fixed as Wednesday, March 11, 2026.Dividend payment will be strictly electronic as per SEBI Fifth Amendment Regulations, 2025.Shareholders must update bank details with Depository Participants to receive funds.The decision was finalized in the Board meeting held on March 05, 2026.
👀 கவனிக்க வேண்டியவை
Investors should ensure their bank account, PAN, and KYC details are updated with their DP by the record date to ensure seamless credit. The stock will likely trade ex-dividend shortly before March 11, 2026.
Bikaji Foods Completes 100% Acquisition of Petunt Food Processors for ₹8 Crore
Bikaji Foods International has finalized the acquisition of the remaining 48.78% stake in Petunt Food Processors Private Limited (PFPPL), making it a wholly-owned subsidiary. The transaction was completed for a cash consideration of ₹8 crore, aimed at consolidating control over operations in the South Indian territory. PFPPL has demonstrated steady growth, with turnover rising from ₹36.36 crore in FY23 to ₹52.07 crore in FY25. This move allows Bikaji to fully integrate PFPPL's manufacturing and distribution capabilities into its core FMCG business.
முக்கிய அம்சங்கள்
Acquired remaining 48.78% stake (35,98,998 shares) for a cash consideration of ₹8 crorePFPPL turnover increased to ₹52.07 crore in FY25, up from ₹42.70 crore in FY24Target entity is now a 100% Wholly-Owned Subsidiary of Bikaji FoodsStrategic focus on strengthening operational control and footprint in the South Indian marketAcquisition completed on March 06, 2026, following the board approval in November 2025
👀 கவனிக்க வேண்டியவை
Investors should look favorably on this consolidation as it simplifies the corporate structure and gives Bikaji full control over a growing regional asset. The acquisition cost seems attractive relative to the target's ₹52 crore annual turnover.
India Ratings Assigns 'IND AAA/Stable' to SBI's INR 75 Billion Tier II Bonds; Affirms Ratings
India Ratings has assigned a top-tier 'IND AAA/Stable' rating to SBI's new INR 75 billion Basel III Tier II bonds while affirming existing ratings for its infrastructure and AT1 bonds. The bank continues to dominate the Indian banking sector with a 22.5% deposit market share and 19.4% share in net advances as of FY25. Asset quality remains a key strength, with GNPA improving to 1.57% and NNPA at 0.39% in 9MFY26. Management expects to maintain a Return on Assets (RoA) of around 1.1% and credit growth between 12-14% for FY26.
முக்கிய அம்சங்கள்
Assigned 'IND AAA/Stable' to new INR 75 billion Tier II bonds and affirmed 'IND AAA' for INR 400 billion infra bonds.Gross NPA improved to 1.57% and Net NPA to 0.39% as of 9MFY26, surpassing most public sector peers.Maintains a dominant 22.5% market share in deposits and 19.4% in advances with a massive network of 23,125 branches.Capital adequacy remains stable with a CET1 ratio of 10.99% and a target Return on Equity (RoE) exceeding 15%.Liquidity remains superior with a Liquidity Coverage Ratio (LCR) of 137.61% as of December 2025.
👀 கவனிக்க வேண்டியவை
The affirmation of the highest credit ratings underscores SBI's systemic importance and robust balance sheet. Investors can remain confident in the bank's stability and its ability to maintain profitability despite minor NIM pressures.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
NBIFIN Shareholders Approve Object Clause Alteration and New Director Appointments
N. B. I. Industrial Finance Company Limited (NBIFIN) has announced the successful passage of three key resolutions via postal ballot with overwhelming shareholder support. Approximately 99.97% of votes were cast in favor of altering the company's Object Clause, providing potential for business diversification. Additionally, shareholders approved the appointments of Shri Mohan Bangur and Shri Prashant Bangur as Non-Executive Non-Independent Directors. The voting process, which concluded on March 4, 2026, reflects strong investor confidence in the current management and strategic direction.
முக்கிய அம்சங்கள்
Special Resolution to alter the Object Clause passed with 2,12,69,019 votes (99.97%) in favorAppointment of Shri Mohan Bangur as Non-Executive Non-Independent Director approved with 99.97% majorityAppointment of Shri Prashant Bangur as Non-Executive Non-Independent Director approved with 99.97% majorityOnly 715 votes were cast against each of the three resolutions, showing high consensusThe voting period was conducted from February 3, 2026, to March 4, 2026
👀 கவனிக்க வேண்டியவை
Investors should view the high approval rates as a sign of management stability and monitor future announcements regarding how the altered Object Clause will be utilized for business expansion.
SBI Life Tax Demand Reduced by ₹4,846 Crore to ₹470.88 Crore Following Rectification
SBI Life Insurance has received a significant rectification order from the Income Tax Department for FY 2021-22, correcting a previously erroneous demand. The total tax and interest demand has been slashed from ₹5,317.18 crore to ₹470.88 crore after the company filed a rectification application highlighting calculation errors. This reduction of over 90% in the potential liability provides substantial financial relief. The company is continuing its appeal against the remaining demand before the Commissioner (Appeals).
முக்கிய அம்சங்கள்
Total tax demand for FY 2021-22 reduced from ₹5,317.18 crore to ₹470.88 croreTax component specifically decreased from ₹4,286.63 crore to ₹315.84 croreInterest component slashed from ₹1,030.55 crore to ₹155.04 croreRectification order issued under Section 154 of the Income Tax Act, 1961Company maintains its appeal against the revised demand at the Commissioner Appeals level
👀 கவனிக்க வேண்டியவை
This massive reduction in tax demand removes a significant financial overhang and is a major positive for the stock. Investors should continue to monitor the final resolution of the remaining ₹470.88 crore appeal.
A B Infrabuild Secures ₹62.94 Crore NHAI Project in Odisha
A B Infrabuild Limited has received a Letter of Acceptance from the National Highways Authority of India (NHAI) for a road infrastructure project in Odisha. The contract involves the construction of three Vehicular Underpasses (VUPs) and associated service roads on NH-16. The total value of the order is approximately ₹62.94 Crore, to be executed within an 18-month timeframe. This domestic project on EPC mode strengthens the company's order book and revenue visibility.
முக்கிய அம்சங்கள்
Contract awarded by National Highways Authority of India (NHAI) for work on NH-16 in Odisha.Total order value stands at ₹62.94 Crore (Rs. 62,94,04,813.35).Project scope includes construction of 3 Vehicular Underpasses (VUPs) and service roads.The project is to be executed on EPC mode within a period of 18 months.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development for the company's order book and monitor execution progress. The successful completion of this NHAI project could lead to larger contract opportunities in the future.
Biocon to Invest Rs 315.34 Crore in Subsidiaries Biocon Biosphere and Biocon Pharma
Biocon Limited has announced a total investment of Rs 315.34 crore into its wholly owned subsidiaries, Biocon Biosphere Limited (BBSL) and Biocon Pharma Limited (BPL). The investment is structured through the acquisition of Optionally Convertible Redeemable Non-Cumulative Preference Shares (OCRPS). For BBSL, the investment of Rs 115.34 crore involves a cash infusion of Rs 20 crore and the conversion of existing loans worth Rs 95.34 crore. For BPL, the company is injecting Rs 200 crore in cash to support working capital and general corporate requirements.
முக்கிய அம்சங்கள்
Total investment of Rs 315.34 crore across two wholly owned subsidiaries via OCRPS at Rs 10 per share.Biocon Pharma Limited (BPL) receives Rs 200 crore in cash for working capital and corporate needs.Biocon Biosphere Limited (BBSL) receives Rs 115.34 crore, including conversion of Rs 95.34 crore debt and interest into equity-like instruments.BPL showed steady growth with FY25 turnover reaching Rs 9,825 million compared to Rs 8,816 million in FY24.BBSL is scaling up operations with turnover rising from Rs 6 million in FY24 to Rs 130 million in FY25.
👀 கவனிக்க வேண்டியவை
This is a routine internal capital allocation to support the growth and working capital needs of subsidiaries. Investors should monitor if this funding helps BPL and BBSL achieve better profitability and scale in the generic formulations and API segments.
Fitch Upgrades SBI's Viability Rating to 'bb+'; Affirms Long-Term IDR at 'BBB-'
Fitch Ratings has upgraded State Bank of India's (SBI) Viability Rating (VR) to 'bb+' from 'bb', citing sustained improvements in asset quality, capitalization, and profitability. The bank's Long-Term Issuer Default Rating (IDR) was affirmed at 'BBB-' with a Stable outlook, reflecting its systemic importance and strong government support. SBI's Common Equity Tier 1 (CET1) ratio saw a significant jump to 12.6% in 9MFY26 from 10.8% in FY25. Asset quality remains healthy with an impaired-loan ratio of 1.6% and a robust liquidity coverage ratio of 138%.
முக்கிய அம்சங்கள்
Viability Rating (VR) upgraded to 'bb+' from 'bb' reflecting improved intrinsic financial strength.CET1 ratio increased to 12.6% in 9MFY26 from 10.8% in FY25, bolstered by a 2025 equity raise.Impaired-loan ratio improved to 1.6% as of 9MFY26, with Fitch forecasting it to stay at this level through FY27.Customer deposits comprise 90% of total funding, highlighting a very stable liquidity profile.Operating profit/risk-weighted asset ratio expected to remain steady at approximately 2.5%.
👀 கவனிக்க வேண்டியவை
The upgrade in the viability rating underscores SBI's strengthening balance sheet and superior risk oversight compared to state-owned peers. Investors should view this as a positive reinforcement of the bank's dominant market position and improved capital cushions.
Panacea Biotec Receives ₹45.71 Crore Income Tax Demand for AY 2015-16
Panacea Biotec has received a demand order of ₹45.71 crore from the Income Tax Department for the Assessment Year 2015-16. The demand stems from the disallowance of certain expenditures under Section 37 of the IT Act, which the authorities allege violated Medical Council of India (MCI) regulations. The company contends that the demand is misplaced as it has sufficient brought-forward losses to offset any taxable income. Management is currently pursuing legal remedies, including filing a rectification application and an appeal before the relevant authorities.
முக்கிய அம்சங்கள்
Total tax demand of ₹45.71 crore including interest for Assessment Year 2015-16.Demand issued by the Deputy Commissioner of Income Tax, Central Circle 29, Delhi.Disallowances based on alleged violations of Medical Council of India (MCI) Regulations.Company claims no actual tax liability due to availability of brought-forward losses.Legal recourse initiated via rectification application and appellate authority appeal.
👀 கவனிக்க வேண்டியவை
Investors should monitor the progress of the appeal and rectification process, as any final unfavorable ruling could impact the company's financial position despite the current claim of tax losses.
SBI Life Seeks Approval for ₹70,900 Cr+ Related Party Transactions for FY 2026-27
SBI Life Insurance has issued a postal ballot notice seeking shareholder approval for material related party transactions (RPTs) for the upcoming financial year 2026-27. The company proposes transactions with State Bank of India (SBI) totaling ₹40,900 crore and with SBI DFHI Limited totaling ₹30,000 crore. These transactions primarily involve investment purchases and sales, premium income, and commission expenses conducted at arm's length. Shareholders can cast their votes via e-voting from March 1 to March 30, 2026.
முக்கிய அம்சங்கள்
Proposed RPT with State Bank of India (SBI) capped at ₹40,900 crore for FY 2026-27.Proposed RPT with SBI DFHI Limited capped at ₹30,000 crore for investment-related activities.SBI transactions include ₹15,000 crore for investment purchases and ₹4,400 crore for commission expenses.Premium income from SBI-related business is estimated at ₹6,000 crore for the fiscal year.E-voting period is scheduled from March 1, 2026, to March 30, 2026, with results by April 2, 2026.
👀 கவனிக்க வேண்டியவை
This is a routine regulatory requirement for listed companies to approve transactions with parent and group entities. Investors should note the scale of synergy with SBI, which remains a key driver for the company's distribution and investment strategy.
SBI Cards Board to Consider Interim Dividend on March 5; Record Date Set for March 11
SBI Cards and Payment Services Limited has scheduled a Board meeting on March 5, 2026, to consider and potentially declare an interim dividend for the financial year 2025-26. The company has proactively fixed March 11, 2026, as the record date to determine shareholder eligibility for the payout. In compliance with insider trading regulations, the trading window for the company's securities is closed from February 27 to March 7, 2026. This announcement indicates the company's intent to share profits with its investors.
முக்கிய அம்சங்கள்
Board meeting scheduled for March 5, 2026, to consider interim dividend declaration.Record date for dividend eligibility fixed as March 11, 2026.Trading window for designated persons closed from February 27 to March 7, 2026.Dividend consideration pertains to the financial year 2025-26.
👀 கவனிக்க வேண்டியவை
Investors should monitor the Board meeting outcome on March 5 for the specific dividend amount. To be eligible for the dividend, ensure shares are held in the demat account before the ex-dividend date.
Concord Biotech Q3 Revenue Up 14% YoY to ₹278 Cr; PAT Dips 8.5% on Exceptional Costs
Concord Biotech reported a 13.9% YoY increase in revenue from operations to ₹27,813 lakhs for Q3 FY26. However, Net Profit (PAT) declined by 8.5% YoY to ₹6,778 lakhs, primarily impacted by a one-time exceptional charge of ₹327.54 lakhs related to new labour code regulations. On a sequential basis, the company showed recovery with revenue and PAT growing 12.6% and 7.8% respectively compared to Q2 FY26. The board also strengthened its leadership by appointing Mr. Paritosh Trivedi as the new Company Secretary and Compliance Officer.
முக்கிய அம்சங்கள்
Revenue from operations grew 13.9% YoY to ₹27,813.39 lakhs in Q3 FY26 compared to ₹24,422.02 lakhs in Q3 FY25.Net Profit (PAT) for the quarter stood at ₹6,778.27 lakhs, a decline from ₹7,408.88 lakhs in the corresponding quarter last year.Recognized an exceptional item of ₹327.54 lakhs due to the statutory impact of new labour codes on employee benefit obligations.9-month PAT for FY26 shows a significant decline to ₹17,324.46 lakhs from ₹23,102.69 lakhs in the same period last year.Appointed Mr. Paritosh Trivedi as Company Secretary and Compliance Officer effective February 11, 2026.
👀 கவனிக்க வேண்டியவை
Investors should monitor the margin pressure as PAT has declined despite healthy revenue growth. The significant year-to-date profit lag compared to the previous fiscal suggests a cautious outlook until bottom-line growth stabilizes.
SBI Life Declares Interim Dividend of ₹2.70 Per Share for FY 2025-26
SBI Life Insurance has declared an interim dividend of ₹2.70 per equity share for the financial year 2025-26, which represents 27% of the face value. The company has established March 06, 2026, as the record date for determining shareholder eligibility, with the payout scheduled to be completed by March 27, 2026. Furthermore, the board is seeking shareholder approval via postal ballot for material related party transactions with State Bank of India and other group entities for the upcoming fiscal year 2026-27. This announcement underscores the company's consistent dividend policy and proactive regulatory planning for its bancassurance operations.
முக்கிய அம்சங்கள்
Interim dividend of ₹2.70 per equity share declared for FY 2025-26Record date for dividend entitlement is fixed as March 06, 2026Dividend payment to be processed on or before March 27, 2026Shareholder approval sought for material related party transactions with SBI and affiliates for FY 2026-27Postal ballot e-voting period scheduled from March 01 to March 30, 2026
👀 கவனிக்க வேண்டியவை
Investors interested in the dividend should ensure they hold the stock before the record date of March 06, 2026. The related party transactions are standard for SBI Life's business model and are unlikely to impact the stock's fundamental valuation.
Biocon to Consolidate 100% of Biologics Unit; Net Debt/EBITDA Drops to 2.8x
Biocon is integrating its Generics and Biosimilars businesses to simplify its corporate structure and remove the holding company discount. The company has successfully reduced its Net Debt/EBITDA from 4.3x to 2.8x following a ₹4,500 crore QIP and strategic refinancing of $1.2 billion. This deleveraging is expected to result in annual interest savings of approximately ₹300 crore. With major CapEx cycles largely completed, the company is now focusing on a pipeline of 30+ biosimilars and 3 GLP-1 products targeting a $200 billion market opportunity.
முக்கிய அம்சங்கள்
Raised ₹4,500 crore via QIP to redeem structured debt, saving ₹300 crore in annual interest costs.Net Debt/EBITDA leverage improved significantly from 4.3x in FY23 to 2.8x in 9MFY26.Board approved acquiring the remaining ~2% stake in Biocon Biologics to achieve 100% ownership.Refinanced $1.2 billion in debt, including an $800 million bond, extending maturity by 5 years.Future growth driven by 30+ biosimilars and 3 GLP-1s addressing a $200B+ market opportunity.
👀 கவனிக்க வேண்டியவை
Investors should favor the improved balance sheet and simplified structure which addresses previous concerns regarding high debt and complex subsidiary holdings. Monitor the commercial progress of the GLP-1 pipeline as a key catalyst for future valuation rerating.
Biocon Obtains US FDA Approval for Liraglutide (gSaxenda) Weight Management Drug
Biocon has received US FDA approval for its generic version of Saxenda (Liraglutide), a drug-device combination for chronic weight management. This approval marks a significant entry into the high-growth GLP-1 therapy market in the United States, which had an addressable market of $127 million as of December 2025. The product is a 18 mg/3 mL prefilled pen, validating Biocon's vertically integrated manufacturing capabilities. This development is expected to be a key revenue driver for Biocon's US generics business in the coming years.
முக்கிய அம்சங்கள்
Received US FDA approval for Liraglutide Injection 18 mg/3 mL (6 mg/mL) prefilled pens.Targets the US GLP-1 weight loss market, valued at approximately $127 million in 2025.First-of-its-kind drug-device combination approval for Biocon in the GLP-1 category.Strengthens Biocon's position in one of the fastest-growing therapeutic classes globally.
👀 கவனிக்க வேண்டியவை
Investors should view this as a major positive catalyst for Biocon's US portfolio expansion. Monitor the commercial launch timeline and market share capture in the competitive GLP-1 segment.
Triveni Turbine Seeks Re-appointment of Nikhil Sawhney as MD for 5-Year Term
Triveni Turbine Limited has issued a postal ballot notice to seek shareholder approval for the re-appointment of Mr. Nikhil Sawhney as Managing Director, designated as Vice Chairman and Managing Director. The proposed tenure is for a period of five years, effective from May 10, 2026. The voting process will be conducted via remote e-voting, starting from February 25, 2026, and concluding on March 26, 2026. This move is intended to ensure leadership stability and continuity in the company's strategic management.
முக்கிய அம்சங்கள்
Proposed re-appointment of Mr. Nikhil Sawhney as Managing Director for a 5-year term starting May 10, 2026Remote e-voting period set from February 25, 2026, 9:00 A.M. to March 26, 2026, 5:00 P.M.Cut-off date for eligibility to vote is February 20, 2026Results of the postal ballot to be declared on or before March 30, 2026The resolution is proposed as a Special Resolution requiring requisite majority approval
👀 கவனிக்க வேண்டியவை
Investors should monitor the voting results to confirm leadership continuity, which is generally positive for long-term stability. No immediate action is required other than participating in the e-voting process if desired.
MobiKwik Receives BSE Approval to Launch Stock Broking Business Effective Feb 24, 2026
One MobiKwik Systems' subsidiary, MSBPL, has received final approval from the BSE to commence stock broking operations starting February 24, 2026. This follows the SEBI registration obtained in July 2025, allowing the company to offer equity trading, clearing, and settlement services. With a massive user base of over 186.6 million registered users, MobiKwik is well-positioned to cross-sell broking services to its existing digital wallet and payment customers. This move marks a significant step in the company's transition into a comprehensive financial services provider.
முக்கிய அம்சங்கள்
BSE approval received for stock broking; operations to commence from February 24, 2026.Follows SEBI registration granted in July 2025, completing regulatory requirements for the subsidiary MSBPL.MobiKwik currently serves over 186.6 million registered users and 4.79 million merchants.Company holds an 18% market share in the PPI wallet gross transaction value as of December 2025.
👀 கவனிக்க வேண்டியவை
Investors should monitor the adoption rate of the broking platform among MobiKwik's existing 186 million users as it competes with established discount brokers. Successful scaling of this business could significantly enhance the company's average revenue per user (ARPU).
SBI Life to Consider Interim Dividend on Feb 25; Record Date Set for March 06, 2026
SBI Life Insurance Company has scheduled a board meeting on February 25, 2026, to deliberate on the declaration of an interim dividend for the financial year 2025-26. The company has proactively fixed March 06, 2026, as the record date to identify eligible shareholders for the potential payout. In compliance with insider trading regulations, the trading window for designated persons is closed from February 21 to February 27, 2026. This move indicates the company's intent to distribute surplus cash to its shareholders.
முக்கிய அம்சங்கள்
Board meeting scheduled for February 25, 2026, to consider interim dividend for FY 2025-26Record date for dividend eligibility fixed as March 06, 2026Trading window for insiders closed from February 21 to February 27, 2026The dividend amount will be determined during the upcoming board meeting
👀 கவனிக்க வேண்டியவை
Investors should watch for the dividend amount announcement on February 25 and ensure they hold shares before the ex-dividend date to qualify for the payout.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
